First-Line Nivolumab Plus Relatlimab vs Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

home / between-the-lines / first-line-nivolumab-plus-relatlimab-vs-nivolumab-plus-ipilimumab-in-advanced-melanoma-an

Panelists discuss how nivolumab plus relatlimab may offer a similar efficacy to nivolumab plus ipilimumab in advanced melanoma, with a potentially better safety profile, based on an indirect treatment comparison using data from the RELATIVITY-047 and CheckMate 067 trials.

Treatment Decisions in Metastatic Melanoma: Immunotherapy vs Targeted Therapy

EP. 1: Treatment Decisions in Metastatic Melanoma: Immunotherapy vs Targeted Therapy

Ahmad A. Tarhini, MD, PhD;Hussein Abdul-Hassan Tawbi, MD, PhD
December 2nd 2024

Panelists discuss how treatment decisions in metastatic melanoma involve balancing the benefits of immunotherapy versus targeted therapy, taking into account factors such as tumor genetics, patient response, and tolerability.

Key Takeaways from the RELATIVITY-047 Trial: Managing Advanced Melanoma

EP. 2: Key Takeaways from the RELATIVITY-047 Trial: Managing Advanced Melanoma

Ahmad A. Tarhini, MD, PhD;Hussein Abdul-Hassan Tawbi, MD, PhD
December 2nd 2024

Panelists discuss how the RELATIVITY-047 trial data highlights the efficacy of nivolumab plus relatlimab in managing advanced melanoma, offering improved progression-free survival with a favorable safety profile compared to with nivolumab alone.